Clinical trials: Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)

Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome

Burosumab for CSHS

• Completed
• Age: All ages
• Early Phase 1

Burosumab (also known as the drug, Crysvita®) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum…

Trial name

NCT03993821

Testing

Burosumab

Where

United States

Volunteers

1 people

Sponsor

Laura Tosi